Credit Suisse Downgrades GoodRx Holdings to Neutral, Lowers Price Target to $27
Credit Suisse analyst Jailendra Singh downgrades GoodRx Holdings (NASDAQ:GDRX) from Outperform to Neutral and lowers the price target from $41 to $27.
27 Stocks Moving in Monday’s Pre-Market Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday.
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Jim Cramer Shares His Thoughts On AT&T, GoodRx And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he doesn’t hate AT&T Inc. (NYSE: T) anymore.
Ominous Death Cross Forms On GoodRx Holdings’s Chart
If history is any guide, there may be trouble ahead for shares of GoodRx Holdings (NASDAQ:GDRX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Analyst Ratings For GoodRx Holdings
Within the last quarter, GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings:
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Raises Price Target to $41
Morgan Stanley maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and raises the price target from $38 to $41.
Jefferies Initiates Coverage On GoodRx Holdings with Buy Rating, Announces Price Target of $47
Jefferies analyst Glen Santangelo initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Buy rating and announces Price Target of $47.